Intellia Therapeutics is trading 5% down at $14.67 as investors react to a wave of insider stock sales disclosed in early July, which has added selling pressure following a prior rally.
- The stock’s pullback follows earlier positive Phase 3 HAELO trial results and a subsequent equity offering, leading to a period of consolidation.
- Current market sentiment is tempered by profit-taking and insider activity rather than any new fundamental setbacks to the company's clinical pipeline.